Last updated on August 2018

B/F/TAF FDC in HIV-1 Infected Virologically Suppressed Adolescents and Children


Brief description of study

The primary objectives of this study are to evaluate the steady state pharmacokinetics (PK) for bictegravir (GS-9883) and confirm the dose of bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy; B/F/TAF) fixed-dose combination (FDC) in HIV-1 infected, virologically suppressed adolescents (12 to < 18 years of age) and children (6 to < 12 years of age). This study will also evaluate the safety and tolerability of B/F/TAF FDC through Week 24 in HIV-1 infected, virologically suppressed adolescents and children.

Clinical Study Identifier: NCT02881320

Contact Investigators or Research Sites near you

Start Over

Cape Town, South Africa
1.84miles